Acne Vulgaris Clinical Trial
| Verified date | April 2008 |
| Source | Dow Pharmaceutical Sciences |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | United States: Food and Drug Administration |
| Study type | Interventional |
The purpose of this study is to assess the effectiveness of IDP-110 in treating patients with acne vulgaris.
| Status | Completed |
| Enrollment | 1414 |
| Est. completion date | |
| Est. primary completion date | August 2007 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 12 Years to 70 Years |
| Eligibility |
Inclusion Criteria: - Presence of inflammatory and non-inflammatory lesions Exclusion Criteria: - Dermatological conditions of the face other than acne that could interfere with clinical evaluations - Female subjects who are pregnant, nursing, planning a pregnancy, or become pregnant during the study |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
| Country | Name | City | State |
|---|---|---|---|
| Belize | Dermatology and Skin Surgery Centre | Belize City | |
| Canada | Mediprobe Research | New London | Ontario |
| United States | Academic Dermatology | Albuquerque | New Mexico |
| United States | Total Skin and Beauty Dermatology Center | Birmingham | Alabama |
| United States | University of Alabama, Birmingham | Birmingham | Alabama |
| United States | Office of Scott Glazer, MD | Buffalo Grove | Illinois |
| United States | Triangle Medical Research Associates | Cary | North Carolina |
| United States | Cherry Creek Dermatology Research Inc. | Denver | Colorado |
| United States | Henry Ford Medical Center | Detroit | Michigan |
| United States | Rivergate Dermatology | Goodlettsville | Tennessee |
| United States | Unifour Medical Research Associates | Hickory | North Carolina |
| United States | The Center for Skin Research | Houston | Texas |
| United States | Medical Affiliated Research Center, Inc. | Huntsville | Alabama |
| United States | Dermatology Associates | Knoxville | Tennessee |
| United States | Dermatology Research of Arkansas | Little Rock | Arkansas |
| United States | Longmont Medical Research Network | Longmont | Colorado |
| United States | FXM Research | Miami | Florida |
| United States | International Dermatology Research, Inc. | Miami | Florida |
| United States | Advanced Healthcare | Milwaukee | Wisconsin |
| United States | Dermatology Research Associates | Nashville | Tennessee |
| United States | Tennessee Clinical Research Center | Nashville | Tennessee |
| United States | Northwest Cutaneous Research Specialists | Portland | Oregon |
| United States | Oregon Medical Center, PC | Portland | Oregon |
| United States | Wake Research Associates, LLC | Raleigh | North Carolina |
| United States | The Nevada Center for Dermatology | Reno | Nevada |
| United States | Dermatology Resarch Center | Salt Lake City | Utah |
| United States | Progressive Clinical Research | San Antonio | Texas |
| United States | Affiliated Research Institute - Dermatology | San Diego | California |
| United States | Therapeutics Clinical Research | San Diego | California |
| United States | University of California, San Diego, Pediatric and Adolescent Dermatology | San Diego | California |
| United States | Solano Clinical Research | Vallejo | California |
| United States | Dermatology Specialists, Inc. | Vista | California |
| United States | Advanced Clinical Research - Jordan Valley | West Jordan | Utah |
| United States | Clinical Research Specialists | West Santa Monica | California |
| United States | New Haven Medical Research | Wilmington | North Carolina |
| Lead Sponsor | Collaborator |
|---|---|
| Dow Pharmaceutical Sciences |
United States, Belize, Canada,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Change from baseline in number of lesions | 12 weeks | No | |
| Secondary | Change from baseline in global severity | 12 weeks | No |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04321070 -
Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris
|
Phase 1 | |
| Recruiting |
NCT05755256 -
The Impact of Probiotics on Skin Hydration in Youth With Mild Acne
|
Phase 2 | |
| Completed |
NCT05131373 -
Safety, Tolerability, and Immunogenicity of ORI-A-ce001 for the Treatment of Acne Vulgaris
|
Phase 1 | |
| Completed |
NCT01445301 -
Study STF115287, a Clinical Confirmation Study of GSK2585823 in the Treatment of Acne Vulgaris in Japanese Subjects
|
Phase 3 | |
| Completed |
NCT03303170 -
Non-Significant Risk Study of Sebacia Microparticles in the Treatment of Facial Acne Vulgaris
|
N/A | |
| Completed |
NCT04698239 -
Clinical Evaluation of the Safety and Benefits of the Milesman 445 nm Blue Laser on Inflammatory Acne Lesions.
|
N/A | |
| Completed |
NCT02886715 -
A Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both to a Placebo Control in the Treatment of Acne Vulgaris
|
Phase 3 | |
| Terminated |
NCT02924428 -
Venus Versa Diamondpolar Applicator Treatment Followed by AC Dual Applicator Treatment for Facial Acne Vulgaris
|
N/A | |
| Not yet recruiting |
NCT02525822 -
Study to Compare the Safety and Efficacy of IDP-123 Lotion to Tazorac Cream in the Treatment of Acne Vulgaris
|
Phase 2 | |
| Not yet recruiting |
NCT02491060 -
A Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris
|
Phase 3 | |
| Not yet recruiting |
NCT02535871 -
A Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris
|
Phase 3 | |
| Completed |
NCT02709902 -
Study Comparing Adapalene/BP Gel to EPIDUO® FORTE and Both to a Placebo Control in Treatment of Acne Vulgaris
|
Phase 1 | |
| Completed |
NCT02913001 -
The Effect of a Low Glycemic Load Diet on Hormonal Markers Associated With Acne
|
N/A | |
| Completed |
NCT02250430 -
A Phase 1 Study Assessing Local Cutaneous Effects of SB204
|
Phase 1 | |
| Completed |
NCT01694810 -
Cutaneous Tolerability and Safety of NVN1000 Topical Gel in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT01769664 -
A Study Comparing Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel to Duac® Topical Gel in the Treatment of Acne Vulgaris
|
Phase 1 | |
| Completed |
NCT01727440 -
Identifying the Genetic Predictors of Severe Acne Vulgaris and the Outcome of Oral Isotretinoin Treatment
|
N/A | |
| Completed |
NCT01194375 -
A Dose-Ranging Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris
|
Phase 2 | |
| Completed |
NCT01706250 -
U0289-401: Eight Week, Split-face, Study to Determine and Compare the Efficacy and Tolerability of MAXCLARITY™ II to PROACTIV™
|
Phase 4 | |
| Completed |
NCT02524665 -
8 Week Study to Evaluate and Compare the Efficacy and Tolerability of MAXCLARITY II and MURAD To Treat Acne
|
Phase 4 |